AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00640055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinator
Description: Coordinator (non-physician) assigned cause of death
Study NCT00640055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physician-assigned cause of death
Description: Physician (gold standard) cause of death
Study NCT03065023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
Study NCT02827240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
Study NCT01380639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: performing squats for 3x3 minutes while using vibration platform three times a week
Study NCT02357823 — intervention group
Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23
Study NCT02357823 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization
Study NCT00680823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Study NCT00680823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Study NCT03511404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy rehabilitation
Description: All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
Study NCT01864772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbo, 5FU, Cetuximab
Description: 6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity
Study NCT01353079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Short Ragweed Pollen Allergenic Extract
Description: Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
Study NCT01353079 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Glycero-COCAs sublingual
Study NCT02849301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary
Study NCT00522912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Description: Posterior lamella tarsal rotation
Study NCT00522912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epilation
Description: Epilation of lashes by another well sighted person using quality epilating forceps
Study NCT02877212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
Study NCT01548924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
Study NCT01548924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib + Paclitaxel
Description: * Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days.
Study NCT01655927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01655927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Saline
Study NCT02493894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: PEG solution (80gr/1Litr) each 8 hours for 24 hours
Study NCT02493894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo each 8 hours for 24 hours
Study NCT02493894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: cefazolin 1gram, every 6hours for 2 days
Study NCT02493894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cefazolin
Description: cefazolin 1gram, every 6hours for 2 days
Study NCT04603586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: in 5-6 fractions with CyberKnife
Study NCT04603586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
Study NCT04354090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection
Study NCT03211247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A Viaskin Peanut 250 mcg
Description: Viaskin Peanut 250 mcg, once daily
Study NCT03211247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A Viaskin Peanut 100 mcg
Description: Viaskin Peanut 100 mcg, once daily
Study NCT03211247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part A Placebo
Description: Placebo patch, once daily
Study NCT03211247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B Viaskin Peanut 250 mcg
Description: Viaskin Peanut 250 mcg, once daily
Study NCT03211247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Placebo patch, once daily
Study NCT03701763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Apremilast (CC-10004)
Study NCT03701763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04307277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care + chemotherapy
Description: Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
Study NCT04307277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Surgical excision with external radiotherapy (if applicable)
Study NCT04246086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive IV mosunetuzumab as defined by the study protocol
Study NCT04246086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
Study NCT04246086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide as defined by the study protocol
Study NCT04246086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (SC)
Description: Participants will receive SC mosunetuzumab as defined by the study protocol
Study NCT03073226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Elite
Description: New generation Olympus endoscope
Study NCT03073226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Spectrum
Description: Current generation Olympus endoscope
Study NCT02947477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmoTrak
Description: Ecological Momentary Assessment of Emotion through Iphone App
Study NCT00782288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digitoxin
Description: 0.05mg tabs, once daily for 28 days
Study NCT00782288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digitoxin
Description: 0.1mg pills, once daily for 28 days.
Study NCT00782288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pill taken once daily for 28 days
Study NCT02764450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astralis 10 HPM
Description: The cavity to be filled is in quadrant I or III
Study NCT02764450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astralis 10 RM
Description: The cavity to be filled is in quadrant II or IV
Study NCT04339114 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breakfast: control meal
Description: The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
Study NCT04339114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: Cinnamon meal
Description: The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
Study NCT04339114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: Italian herbs meal
Description: The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
Study NCT04339114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: pumpkin spice
Description: The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
Study NCT00174265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5-10 mg sublingually twice daily for 26 weeks
Study NCT00174265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study NCT01119326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Transfer
Description: one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
Study NCT01119326 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fat Transfer
Description: one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
Study NCT02342756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeting transpulmonary pressure to avoid VILI
Description: Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
Study NCT03359213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 1.0 mg/kg/week
Study NCT03359213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 2.0 mg/kg/week
Study NCT03359213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 4.0 mg/kg/week
Study NCT02204566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the esophagus using the OFDI Capsule and system
Study NCT00047320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00047320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00047320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00047320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00047320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00047320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00047320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00047320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00047320 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: craniospinal irradiation
Study NCT01875536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
Study NCT01875536 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional physical therapy
Description: The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
Study NCT01875536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
Study NCT00064389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate HFA MDI
Description: levalbuterol MDI 90 mcg QID
Study NCT00064389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol
Description: racemic albuterol HFA MDI 180 mcg QID
Study NCT02429297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITCM-only
Description: HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
Study NCT02429297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITCM+CP
Description: HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
Study NCT02903069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ
Description: MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion.
Study NCT02903069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment.
Study NCT02903069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
Study NCT02903069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
Study NCT03176563 — intervention group
Intervention type: DRUG
Intervention: Arctuvan
Description: application of a herbal drug in the clinical trial REGATTA (NCT03151603)
Study NCT03176563 — intervention group
Intervention type: DRUG
Intervention: Placebo to Fosfomycin
Description: application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
Study NCT03176563 — intervention group
Intervention type: DRUG
Intervention: Fosfomycin
Description: application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
Study NCT03176563 — intervention group
Intervention type: DRUG
Intervention: Placebo to Arctuvan
Description: application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
Study NCT02818920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications
Study NCT04760886 — intervention group
Intervention type: OTHER
Intervention: Type of hospital (rural DGH vs Urban MTC)
Description: In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
Study NCT03435016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic work-up
Description: Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
Study NCT00445068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT00523120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: topical solution used in ear 5 drops 8 3/day
Study NCT00523120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexotc
Description: aural drops
Study NCT05179642 — intervention group
Intervention type: OTHER
Intervention: OPTIM-EHPAD tool
Description: This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents.
Study NCT00411281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given subcutaneously
Study NCT00411281 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: observation
Description: No intervention
Study NCT04711668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intraoperative ketamine bolus and infusion
Study NCT04711668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: intraoperative lidocain bolus and infusion
Study NCT04711668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intraoperative saline bolus and infusion
Study NCT00640484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)
Study NCT00640484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)
Study NCT00640484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)
Study NCT00640484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)
Study NCT04631796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lenses
Description: Silicone hydrogel contact lenses with investigational coating
Study NCT04631796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multipurpose disinfection solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study NCT03118037 — intervention group
Intervention type: DEVICE
Intervention: Sonata System
Description: Transcervical access for radiofrequency ablation of uterine fibroids